<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05613166</url>
  </required_header>
  <id_info>
    <org_study_id>PKU-SJ-01-2021-V1</org_study_id>
    <nct_id>NCT05613166</nct_id>
  </id_info>
  <brief_title>Adjunctive Everolimus Treatment of Refractory Epilepsy</brief_title>
  <official_title>A Prospective, Randomized, Double-blind, Placebo-Controlled Phase â…¡ Study to Evaluate the Efficacy of Adjunctive Everolimus Treatment in Patients With Refractory Epilepsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Drug Dependence, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shengjing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute on Drug Dependence, China</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project is a prospective, randomized, placebo-controlled, double-blind study that will&#xD;
      evaluate the clinical efficacy of everolimus as an adjunctive treatment in adult patients&#xD;
      diagnosed with refractory epilepsy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The project consists of a screening and baseline monitoring period of 1-2 weeks, and a&#xD;
      treatment period of 1 week, followed by a 3-month follow-up period. Approximately 108&#xD;
      participants will be randomized in a blinded manner to one of three arms in a 1:1:1 fashion&#xD;
      (everolimus 1h : everolimus 8-9h : Placebo). After screening, participants will have the&#xD;
      first video-EEG monitoring for up to 24 hours to assess baseline levels, followed by 1 week&#xD;
      of treatment, the second video-EEG monitoring, and a 3-month post treatment follow-up period.&#xD;
      During the treatment period, participants will be given everolimus or placebo directed to&#xD;
      seizure events. In the &quot;everolimus 1h&quot; group, everolimus will be administrated immediately&#xD;
      after seizure events (within 1 hour); while in the &quot;everolimus 8-9h&quot; group, everolimus&#xD;
      administration will be delayed (at 8-9 hours after seizure events). We conduct this study to&#xD;
      assess the efficacy of everolimus in adult refractory epilepsy patients under an&#xD;
      administration strategy in a limited time window immediately after seizure events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 2022</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline frequency of epileptic discharge</measure>
    <time_frame>1 week</time_frame>
    <description>Comparing frequency of epileptic discharge during video-EEG monitoring after versus before treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline seizure frequency</measure>
    <time_frame>6 months</time_frame>
    <description>Comparing number of seizures in 3 months after treatment versus baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline seizure types</measure>
    <time_frame>6 months</time_frame>
    <description>Comparing types of seizures in 3 months after treatment versus baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline frequency of seizure-free days</measure>
    <time_frame>6 months</time_frame>
    <description>Comparing seizure-free days in 3 months after treatment versus baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seizure-free rate</measure>
    <time_frame>3 months</time_frame>
    <description>Patients remaining seizure free in 3 months after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline occurrence of secondary generalized seizure and status epilepticus</measure>
    <time_frame>6 months</time_frame>
    <description>Comparing number of occurrence of secondary generalized seizure and status epilepticus in 3 months after treatment versus baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire (QOLIE-31-Chinese version) scores</measure>
    <time_frame>3 months</time_frame>
    <description>Comparing the scores at 3 months after treatment versus before treatment</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>everolimus 1h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study participants will orally receive everolimus within 1 hour and placebo at 8-9 hours after each seizure event, but with intervals longer than 24 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>everolimus 8-9h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study participants will orally receive placebo within 1 hour and everolimus at 8-9 hours after each seizure event, but with intervals longer than 24 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The study participants will orally receive placebo both within 1 hour and at 8-9 hours after each seizure event, but with intervals longer than 24 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Everolimus will be administrated orally based on seizure events, with an administration interval longer than 24 hours. Participates with a body surface area (BSA) of &lt;= 1.2 m^2, the dosage was 2.5 mg/time; for BSA 1.3-2.1 m^2, the dosage was 5 mg/time; and for BSA &gt;=2.2 m^2, the dosage was 7.5 mg/time.</description>
    <arm_group_label>everolimus 1h</arm_group_label>
    <arm_group_label>everolimus 8-9h</arm_group_label>
    <other_name>Afinitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Vitamin C</description>
    <arm_group_label>everolimus 1h</arm_group_label>
    <arm_group_label>everolimus 8-9h</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of drug resistant epilepsy, with treatment of at least two approved&#xD;
             anti-epileptic drugs (AEDs), and having at least one reported seizure per month during&#xD;
             the 3-month baseline phase and no continuous 3-month seizure-free period.&#xD;
&#xD;
          -  Diagnosis of focal epilepsy without secondary generalization.&#xD;
&#xD;
          -  Treatment with a stable dose of AEDs that must have no drug interactions with&#xD;
             everolimus (eg, valproic acid, topiramate, oxazepine, phenobarbital, phenytoin, and&#xD;
             primidone) for at least 12 weeks before enrollment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of non-drug treatment for epilepsy, eg, vagus nerve stimulation (VNS),&#xD;
             ketogenic diet, and epilepsy surgery.&#xD;
&#xD;
          -  Severe dysfunction in kidney.&#xD;
&#xD;
          -  With significant infectious, immunologic, or oncologic comorbidity at the time of&#xD;
             enrollment.&#xD;
&#xD;
          -  Currently taking or previously treated systemically with an mammilian target of&#xD;
             rapamycin (mTOR) inhibitor.&#xD;
&#xD;
          -  History of seizures secondary to drug abuse, psychogenic nonepileptic seizures, or an&#xD;
             episode of status epilepticus within 1 year before enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Weining Ma, MD.</last_name>
    <phone>86-024-96615-36316</phone>
    <email>maweining1985@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shengjing Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weining Ma, MD.</last_name>
      <phone>86-024-96615-36316</phone>
      <email>maweining1985@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 5, 2022</study_first_submitted>
  <study_first_submitted_qc>November 5, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2022</study_first_posted>
  <last_update_submitted>November 5, 2022</last_update_submitted>
  <last_update_submitted_qc>November 5, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>everolimus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Drug Resistant Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

